FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1986153892> ?p ?o ?g. }

• W1986153892 endingPage "1060" @default.
• W1986153892 startingPage "1051" @default.
• W1986153892 abstract "After completing this course, the reader will be able to: Summarize the main risk factors for relapse in patients with T4 breast cancer after neoadjuvant chemotherapy. Evaluate the role of hormone receptors and HER-2 as determinants of risk of relapse after neoadjuvant treatment. Compare the difference in outcomes between patients who achieve less than pCR in relation to receptor status. This article is available for continuing medical education credit at CME.TheOncologist.com. Pathological complete response (pCR) to primary chemotherapy is the main determinant for improved disease-free survival (DFS) and overall survival (OS). The primary endpoints of our study were the long-term DFS and OS rates in homogeneously treated stage IIIB breast cancer patients who failed to achieve a pCR (<pCR), in relation to residual tumor burden. The secondary endpoint was the prognostic relevance of hormone receptor (HR) and human epidermal growth factor receptor (HER)-2 status. We analyzed 58 of 74 consecutive stage IIIB patients treated between 1996 and 2001 who achieved <pCR following a primary cisplatin, epirubicin, and vinorelbine regimen for up to six cycles. At the time of patient accrual, trastuzumab was not available. After definitive surgery, pathological residual disease remained in 40 (69%) patients in both the breast and axilla, in 14 (24%) patients in only the breast, and in four (7%) patients in only the axilla. Fifty-eight (78%) of 74 patients achieved <pCR and 16 (22%) had pCR both in the breast and axilla. After a median follow-up of 99 months (range, 72–134 months), in patients with <pCR the estimated 10-year DFS and OS rates were 37.6% and 50.3%, respectively, significantly worse than in the pCR group (p = .003 and p = .008, respectively). Patients with four or more axillary nodes involved had a significantly worse 10-year DFS rate (28.9% versus 62.7%; p = .036). Patients with HR− tumors had significantly lower 10-year DFS (17.3% versus 46.4%; p = .018) and OS (17.3% versus 70.2%; p = .002) rates. Overall, the triple-negative (TN) group showed only a marginally significantly worse OS rate (p = .048). HER-2 status alone, in the absence of trastuzumab, did not appear to significantly affect outcomes. Our data suggest that, in stage IIIB patients who achieve <pCR, the number of residual nodes and HR− status are strong predictors of poor outcomes. After a long follow-up time, HER-2 expression does not appear to significantly affect DFS and OS. TN patients showed a trend toward early recurrence and death." @default.
• W1986153892 created "2016-06-24" @default.
• W1986153892 creator A5000261373 @default.
• W1986153892 creator A5012233597 @default.
• W1986153892 creator A5035309020 @default.
• W1986153892 creator A5044926112 @default.
• W1986153892 creator A5054731547 @default.
• W1986153892 creator A5055827780 @default.
• W1986153892 creator A5068234157 @default.
• W1986153892 creator A5079689180 @default.
• W1986153892 creator A5089936869 @default.
• W1986153892 creator A5090814125 @default.
• W1986153892 date "2009-11-01" @default.
• W1986153892 modified "2023-09-26" @default.
• W1986153892 title "Long‐Term Outcomes in Stage IIIB Breast Cancer Patients Who Achieved Less Than a Pathological Complete Response (<pCR) After Primary Chemotherapy" @default.
• W1986153892 cites W1788623134 @default.
• W1986153892 cites W1948838904 @default.
• W1986153892 cites W2001646586 @default.
• W1986153892 cites W2003029412 @default.
• W1986153892 cites W2008111120 @default.
• W1986153892 cites W2025959372 @default.
• W1986153892 cites W2026686462 @default.
• W1986153892 cites W2036294483 @default.
• W1986153892 cites W2039691757 @default.
• W1986153892 cites W2061302727 @default.
• W1986153892 cites W2091805528 @default.
• W1986153892 cites W2096145980 @default.
• W1986153892 cites W2103939496 @default.
• W1986153892 cites W2105476926 @default.
• W1986153892 cites W2107631501 @default.
• W1986153892 cites W2109462843 @default.
• W1986153892 cites W2110934536 @default.
• W1986153892 cites W2112907781 @default.
• W1986153892 cites W2117546979 @default.
• W1986153892 cites W2118605519 @default.
• W1986153892 cites W2132434084 @default.
• W1986153892 cites W2133764807 @default.
• W1986153892 cites W2134915449 @default.
• W1986153892 cites W2138902655 @default.
• W1986153892 cites W2146999964 @default.
• W1986153892 cites W2153481216 @default.
• W1986153892 cites W2154142993 @default.
• W1986153892 cites W2157285286 @default.
• W1986153892 cites W2162760540 @default.
• W1986153892 cites W2165608465 @default.
• W1986153892 cites W2170602872 @default.
• W1986153892 cites W2185945096 @default.
• W1986153892 cites W2232616986 @default.
• W1986153892 cites W4233358210 @default.
• W1986153892 doi "https://doi.org/10.1634/theoncologist.2009-0077" @default.
• W1986153892 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/19897535" @default.
• W1986153892 hasPublicationYear "2009" @default.
• W1986153892 type Work @default.
• W1986153892 sameAs 1986153892 @default.
• W1986153892 citedByCount "4" @default.
• W1986153892 countsByYear W19861538922013 @default.
• W1986153892 crossrefType "journal-article" @default.
• W1986153892 hasAuthorship W1986153892A5000261373 @default.
• W1986153892 hasAuthorship W1986153892A5012233597 @default.
• W1986153892 hasAuthorship W1986153892A5035309020 @default.
• W1986153892 hasAuthorship W1986153892A5044926112 @default.
• W1986153892 hasAuthorship W1986153892A5054731547 @default.
• W1986153892 hasAuthorship W1986153892A5055827780 @default.
• W1986153892 hasAuthorship W1986153892A5068234157 @default.
• W1986153892 hasAuthorship W1986153892A5079689180 @default.
• W1986153892 hasAuthorship W1986153892A5089936869 @default.
• W1986153892 hasAuthorship W1986153892A5090814125 @default.
• W1986153892 hasBestOaLocation W19861538921 @default.
• W1986153892 hasConcept C121608353 @default.
• W1986153892 hasConcept C126322002 @default.
• W1986153892 hasConcept C143998085 @default.
• W1986153892 hasConcept C146357865 @default.
• W1986153892 hasConcept C151730666 @default.
• W1986153892 hasConcept C203092338 @default.
• W1986153892 hasConcept C207886595 @default.
• W1986153892 hasConcept C23589133 @default.
• W1986153892 hasConcept C2776694085 @default.
• W1986153892 hasConcept C2778239845 @default.
• W1986153892 hasConcept C2779013556 @default.
• W1986153892 hasConcept C2779786085 @default.
• W1986153892 hasConcept C2780283643 @default.
• W1986153892 hasConcept C2780350996 @default.
• W1986153892 hasConcept C2780835546 @default.
• W1986153892 hasConcept C2781190966 @default.
• W1986153892 hasConcept C530470458 @default.
• W1986153892 hasConcept C535046627 @default.
• W1986153892 hasConcept C71924100 @default.
• W1986153892 hasConcept C86803240 @default.
• W1986153892 hasConceptScore W1986153892C121608353 @default.
• W1986153892 hasConceptScore W1986153892C126322002 @default.
• W1986153892 hasConceptScore W1986153892C143998085 @default.
• W1986153892 hasConceptScore W1986153892C146357865 @default.
• W1986153892 hasConceptScore W1986153892C151730666 @default.
• W1986153892 hasConceptScore W1986153892C203092338 @default.
• W1986153892 hasConceptScore W1986153892C207886595 @default.
• W1986153892 hasConceptScore W1986153892C23589133 @default.
• W1986153892 hasConceptScore W1986153892C2776694085 @default.
• W1986153892 hasConceptScore W1986153892C2778239845 @default.

• next